- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- rAAV2-CB-hAAT Gene Vector
- Genetic
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2020
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Worcester, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alpha-1 Antitrypsin Deficiency
- Interventions
- Not listed
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Gainesville, Florida • Boston, Massachusetts + 4 more
- Conditions
- Alpha-1 Anti-trypsin Deficiency
- Interventions
- Not listed
- Lead sponsor
- Coram Clinical Trials
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Centennial, Colorado
- Conditions
- Cystic Fibrosis
- Interventions
- Alpha-1 HC 100 mg, Placebo, Alpha-1 HC 200 mg
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Denver, Colorado • Boston, Massachusetts + 3 more
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- Belcesiran, Placebo
- Drug · Other
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- La Jolla, California • Gainesville, Florida • Charleston, South Carolina
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Aralast NP, Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 35 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 15
- States / cities
- La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 10 more
- Conditions
- Alpha1-Antitrypsin Deficiency
- Interventions
- No Intervention
- Other
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Alpha1-antitrypsin Deficiency, Healthy Volunteers
- Interventions
- Alpha1-proteinase inhibitor, Placebo: Human albumin 2.5%
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- VX-634, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Tempe, Arizona • Gainesville, Florida • Orlando, Florida + 2 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- 180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI, Placebo
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 6 Years to 35 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Los Angeles, California • Orange, California + 28 more
- Conditions
- Chronic Obstructive Pulmonary Disease, Acute Exacerbation Copd, Alpha-1 Anti-trypsin Deficiency
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
- Interventions
- Alpha-1 MP
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 20 Years to 72 Years
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Miami, Florida • Wilmington, North Carolina + 3 more
- Conditions
- Alpha1-Antitrypsin Deficiency
- Interventions
- Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human)
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more
- Conditions
- Alpha1-proteinase Inhibitor Deficiency, Emphysema
- Interventions
- Alpha1-proteinase inhibitor, Placebo
- Biological · Other
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Miami, Florida • Hershey, Pennsylvania + 1 more
- Conditions
- Alpha1-antitrypsin Deficiency
- Interventions
- Aerosolized, Recombinant Alpha 1-Antitrypsin
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- BMN 349, Placebo
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- San Diego, California • St Louis, Missouri • Cincinnati, Ohio + 1 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Alpha-proteinase inhibitor
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Cincinnati, Ohio
- Conditions
- Graft-Versus-Host Disease (GVHD) Acute on Chronic
- Interventions
- Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- Kamada-API
- Drug
- Lead sponsor
- Kamada, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Gainesville, Florida • Tyler, Texas
- Conditions
- Pulmonary Emphysema in Alpha-1 PI Deficiency
- Interventions
- Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP
- Biological · Other
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Gainesville, Florida • Leesburg, Florida + 7 more
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- alpha-1 proteinase inhibitor (human)
- Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Gainesville, Florida • Miami, Florida + 5 more
- Conditions
- Alpha 1-Antitrypsin Deficiency, Emphysema
- Interventions
- SAR447537, Zemaira
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
- Conditions
- Emphysema, Lung Diseases, Obstructive, Alpha 1-Antitrypsin Deficiency
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1995 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Graft-versus-host-disease, GVHD
- Interventions
- Alpha 1-Antitrypsin
- Drug
- Lead sponsor
- John Levine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- Duarte, California • Boston, Massachusetts • New York, New York + 2 more